The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Flow-(shear stress-)mediated outward remodeling of resistance arteries is involved in collateral growth during postischemic revascularization. As this remodeling is especially important during pregnancy, we hypothesized that estrogens may be involved. A surgical model eliciting a local increase in blood flow in 1 mesenteric resistance artery was used in 3-month-old ovariectomized female rats either treated with 17-β-estradiol (E2) or left untreated. Methods and Results-After 14 days, arterial diameter was greater in high-flow arteries than in normal-flow vessels. An ovariectomy suppressed high-flow remodeling, while E2 restored it. High-flow remodeling was absent in mice lacking the estrogen receptor α but not estrogen receptor β. The kinetics of inflammatory marker expression, macrophage infiltration, oxidative stress, and metaloproteinases expression were not altered by the absence of E2 after 2 and 4 days, that is, during remodeling. Nevertheless, E2 was required for the increase in endothelial nitric oxide synthase expression and activation at day 4 when diameter expansion occurs. Finally, the impact of E2 on the endothelium appeared crucial for high-flow remodeling, as this E2 action was abrogated in mice lacking endothelial NOS, as well as in Tie2-Cre(+) ERα f/f mice.
C hronic increases in blood flow induce outward hypertrophic remodeling in resistance arteries and improvement of nitric oxide (NO)-dependent dilation. [1] [2] [3] Resistance arteries control local blood flow and their capacity to remodel in response to chronic changes in the hemodynamic environment is necessary to maintain their full efficiency. 4 Chronic increases in blood flow occur in physiological situations, such as growth, pregnancy, or exercise. In response to a chronic increase in blood flow, arterial diameter increases until shear stress is normalized. In addition to angiogenesis, high-flowmediated remodeling of resistance arteries plays a key role in revascularization of ischemic tissues after occlusion of a large artery. 5 The ability of resistance arteries to remodel in response to a chronic increase in blood flow is reduced in rat models of aging, 6, 7 hypertension, 8 and diabetes mellitus. 9 Nevertheless, epidemiological studies have demonstrated that premenopausal women are better protected against cardiovascular diseases than men. 10 Both vascular and cardiac cells express estrogen receptors (ER) α and β, and estrogens have protective properties against atherosclerosis and neointimal proliferation and they accelerate reendothelialization after injury. 10, 11 The decline in ovarian function is furthermore associated with decreased NO production. 12 The reshaping of the arterial wall after a chronic increase in blood flow requires a transient inflammatory response, 13 a moderate oxidative stress, 14 and the activation of the NO pathway. 2 Because estrogens can modulate each of these processes, 15 we investigated whether they play a role in flowmediated outward remodeling of resistance arteries. We used a model in which 2 mesenteric arteries are ligated, leading to a chronic increase in blood flow in the central artery without a change in the systemic hemodynamic environment. 16 We describe here for the first time that 17-β-estradiol (E2) and ERα play a crucial role in the outward remodeling of mesenteric resistance arteries submitted to a chronic increase in blood flow in vivo. To unravel the mechanisms involved in this action of E2 on flow-induced remodeling, the expression of several key molecular actors involved in shear stressmediated remodeling were quantified at the early phases of the remodeling process.
Pressure-Diameter Relationship in Mesenteric Arteries In Vitro
Arterial segments were cannulated at both ends and mounted in a video-monitored perfusion system (Living System, LSI, Burlington, VT). 22, 23 Arteries were bathed in a Ca 2+ -free physiological salt solution containing ethylene-bis-(oxyethylenenitrolo) tetraacetic acid (2 mmol/L) and sodium nitroprusside (10 µmol/L) to determine passive arterial diameter.
Endothelium-Mediated Dilation and Basal NO Production in NF and HF Arteries
Arterial segments (2 mm long each) were mounted in a wire myography and bathed in a physiological salt solution maintained at pH 7.4, PO 2 160 mm Hg, and PCO 2 37 mm Hg. 2, 24 Acetylcholine-mediated relaxation before and after incubation with L-NG-nitroarginine methyl ester (L-NAME) and L-NAME-dependent contraction were obtained after precontraction with phenylephrine. 25
Quantitative Real-Time Polymerase Chain Reaction
The mRNA levels for the following proteins were determined as previously described 26 using real-time polymerase chain reaction: MCP1, CD68, CD11B, COX1, COX2, gp91, p22, p47, metaloproteinases (MMP)2, TIMP1, eNOS, CAV-1, HIF1α, VEGFA, and TGFβ1 on HF and NF mesenteric arteries from OVX rats either treated with E2 or left untreated.
Statistical Analysis
Results were expressed as means±SEM. Significance of the differences between groups was determined by analysis of variance (analysis of variance for consecutive measurements for pressure-diameter curves) or 1-way analysis of variance followed by Bonferroni. Probability values less than 0.05 were considered significant.
Results
After 2 weeks, lumen diameter was greater in HF than in NF arteries ( Figure 1A ). Diameter expansion did not occur in OVX female rats ( Figure 1B) , whereas E2 or raloxifen restored remodeling in OVX animals ( Figure 1C and 1D). E2 blood level and uterus weight were significantly reduced in OVX rats compared with control and with E2-treated OVX rats, whereas no significant difference was observed among groups concerning mean arterial blood pressure ( Figure  I in the online-only Data Supplement). In ERα − / − mice, HF-mediated remodeling was absent, in contrast with WT and ERβ − / − mice ( Figure 2 ). Histological analysis showed that internal and external diameters, wall thickness, and media cross-sectional area were greater in HF than in NF arteries in WT mice, but not in ERα − / − mice ( Figure II in the online-only Data Supplement).
The inflammatory response was evidenced by the presence of the macrophage chemoattractant MCP1 and markers of macrophage CD11b mRNA and CD68 mRNA ( Figure III in the online-only Data Supplement). MCP1 was significantly increased in HF arteries at day 2, but not at day 4. CD68 and CD11b mRNA were significantly higher in HF than in NF vessels at both time points, but the level reached at day 4 was lower than that at day 2. These changes in MCP1, CD11b, and CD68 in HF arteries were not altered by E2. COX2 was significantly higher in E2-treated rats than in untreated OVX rats, whereas COX1 was unaffected ( Figure IV in the online-only Data Supplement). Because COX2 produces vasoactive prostanoids, 27 we treated rats with the COX2 inhibitor celecoxib. 28 Nevertheless, celecoxib did not affect HF remodeling ( Figure  V in the online-only Data Supplement). The inflammatory response occurring at day 2 in HF arteries was confirmed in vessels from WT and ERα − / − mice using immunofluorescence (Figures VI-VIII in the online-only Data Supplement). NAD(P)H-oxidase subunit mRNA levels (p47phox, p22phox, and gp91phox; Figure IX in the online-only Data Supplement) were significantly higher in HF compared with NF arteries in OVX and E2-treated OVX rats after 2 or 4 days (with the exception of p47phox at day 2, where only a trend was observed). Similarly, MMP2 and TIMP mRNA levels increased in HF arteries at day 4, irrespective of the presence or absence of E2 ( Figure X in the online-only Data Supplement).
The eNOS mRNA level was higher in the presence of E2 at day 2 in both NF and HF arteries (there was no significant difference between NF and HF arteries). At day 4, the eNOS mRNA level was higher in HF than in NF arteries in E2-treated rats only ( Figure 3A ). We then functionally assessed the production of NO in arteries submitted to HF at day 4. We found that the inhibitory effect of L-NAME on acetylcholine-mediated dilation was higher in HF arteries from rats treated with E2 than in untreated animals ( Figure XIa in the online-only Data Supplement). In addition, L-NAME-mediated contraction, which reflects basal NO production, was higher in HF than in NF arteries in OVX rats treated with E2, but not in untreated OVX rats ( Figure 3B ). Estradiol-mediated dilation was greater in HF than in NF arteries in E2-treated rats, not in untreated rats ( Figure XIb in the online-only Data Supplement). Finally, we found that the ratio of eNOS protein expression in HF over NF was higher in E2-treated OVX rats than in untreated OVX rats ( Figure 3C ). The ratio of phosphorylated eNOS to total eNOS was also higher in HF arteries than in NF vessels in OVX rats treated with E2, but not in untreated OVX rats ( Figure 3D ).
In contrast with the eNOS mRNA level, caveolin-1 mRNA ( Figure 4A and 4B) and protein ( Figure 4C ) expression levels were lower at day 4 in HF than in NF arteries in OVX rats treated with E2, but not in untreated OVX rats. Furthermore, HF remodeling was absent in eNOS −/− mice, and the absence of caveolin-1 conversely enhanced HF remodeling ( Figure XII in the online-only Data Supplement). In fact, at a pressure of 100 mm Hg, HF artery diameter was 38.5±5.4% greater than that of NF vessels compared with control (23.6±4.3%, n=8, P<0.05, t=2.1585, n=10 per group). In ERα − / − mice, the eNOS mRNA level did not increase and caveolin-1 mRNA level did not decrease in HF arteries compared with NF vessels ( Figure 4D ).
Heme-oxygenase-1 has also been shown to be involved in HF-mediated remodeling. 28 Nevertheless, heme-oxygenase-1 expression level increased in HF arteries in both E2-treated and untreated OVX rats ( Figure XIII in the online-only Data Supplement). This was also observed with TGF b1 ( Figure  XIII in the online-only Data Supplement). On the other hand, HIF1α and VEGF A expression levels ( Figure XIV in the online-only Data Supplement) increased in HF arteries compared with NF vessels only in E2-treated rats.
Because E2 promotes NO production by the endothelial NOS through the activation of ERα, we tested the role of the endothelial ERα in remodeling using Tie2Cre(+)ER f/f mice. Arterial diameter in these mice was not significantly different in HF arteries than in NF vessels, unlike Tie2Cre(+)ERα WT animals ( Figure 5 ).
Discussion
The main finding of this study is that outward remodeling of mesenteric arteries induced by a chronic rise in blood flow relies on estrogens, and more specifically on the activation of endothelial ERα by E2. Physiologically, chronic increases in blood flow in resistance arteries cause diameter expansion with a compensatory increase in wall mass and an increased responsiveness of the endothelium to vasodilator stimuli. 1, 3, 29 The model used in this study offers the unique advantage that blood flow can be increased in one of the numerous equivalent mesenteric arteries without alteration in hemodynamic blood pressure or in circulating hormones. The consequences of this chronic increased flow (and thereby shear stress) in 1 resistance artery can be compared with similar arteries submitted to a normal blood flow in the same vascular bed and in the same animal. 29, 30 Resistance artery outward remodeling is essential to adapt blood flow to tissue needs during growth, pregnancy, and exercise. Remodeling is also essential for revascularization after the occlusion of a large artery, as it allows collateral arteries to grow. 31, 32 Outward remodeling of resistance arteries is also important for a proper response to vasodilator treatments in cardiovascular diseases, including hypertension. 33 Remodeling was abrogated in OVX rats, suggesting that endogenous estrogens play a key role, and remodeling was restored by treatment with exogenous E2. Interestingly, the effect of E2 could be mimicked by raloxifen, a commonly used selective estrogen-receptor modulator that reproduces the action of E2 on bones, but not on the uterus (which suggests another beneficial effect of this widely used selective estrogen-receptor modulator). E2, therefore, appears crucial for diameter enlargement in response to HF. In addition, we then showed that ERα, and not ERβ, was involved in flowmediated diameter enlargement. This finding conforms with the key role of ERα in other beneficial effects of E2, such as acceleration of reendothelialization, 34 prevention of atheroma, 35 promotion of skin flap revascularization, 17 and protection against myocardial ischemia/reperfusion. 36 To identify which step was influenced by ERα activation in the pathway involved in shear stress-mediated remodeling, we isolated arteries 2 and 4 days after ligation. To cause diameter enlargement, flow (shear stress) first induces inflammation and macrophage infiltration (day 1 to day 2), 13 followed by a rise in oxidative stress 14 that favors the formation of peroxinitrite (ONOO − ), which in turn activates MMPs and extracellular matrix digestion between days 3 and 4. 2, 14, 37 The final step requires a dilator stimulus, 13 possibly NO, or inflammatory factors, characterized both in small 14 and in large arteries. 37 In this study, an inflammatory response was evidenced by an early (day 2) rise in MCP1 and macrophage accumulation in the adventitia of HF arteries, consistent with a previous study. 13 This inflammatory response did not appear to be influenced by E2 or by the absence of ERα. In contrast, at day 4, COX2 (the inducible isoform of COX), and not the constitutive COX1, was higher in HF arteries from E2-treated rats compared with untreated animals. This raises the possibility that an increased production of vasodilator prostanoids, such as prostacyclin, 38 could contribute to remodeling. Nevertheless, treating rats with the selective COX2 inhibitor celecoxib 28 did not alter outward remodeling. Similarly, heme-oxygenase-1, the inducible form of the enzyme producing the vasodilator agent CO, was higher at day 4 in HF arteries, in agreement with our previous observations. 28, 39 This increase was observed irrespective of the presence or absence of E2. Oxidative stress and MMPs were similarly activated by the chronic increase in blood flow irrespective of the presence or absence of E2, suggesting that these 2 subsequent steps are not affected by E2.
Finally, we explored the respective roles of eNOS and caveolin-1 in the remodeling process. eNOS expression and activity were both reported to be enhanced by E2 in several species and models. 15 Conversely, caveolin-1 contributes to inhibit eNOS activity. 40 In the present work, we found that the eNOS expression level was higher and caveolin-1 lower in E2-treated rats compared with untreated animals, probably correlating with increased eNOS activity in HF arteries from E2-treated rats. This was confirmed functionally as L-NAMEsensitive relaxation, L-NAME-mediated contraction (reflecting basal NO production), and eNOS phosphorylation were all higher in HF arteries at day 4. The direct vasodilator effect of E2 on mesenteric arteries was also higher in HF arteries than in NF vessels only in OVX rats treated for 2 weeks with E2.
Thus, in HF arteries, diameter expansion could result from NO production because of the increased eNOS expression and activity in endothelial cells. The crucial role of endothelial ERα in flow-mediated remodeling was then demonstrated using Tie2-Cre ERα f/f mice, 35 where ablation of endothelial ERα abrogated the enlargement of HF arteries.
The role of NO-dependent dilation in HF arteries from E2-treated rats was further explored using mice targeted for either eNOS or caveolin-1. As expected, no diameter expansion was observed in HF arteries in eNOS −/− mice. In contrast, diameter expansion was increased in mice lacking caveolin-1 compared with control, independent of the presence or absence of E2. This demonstrates for the first time an important role for caveolin-1 in flow-mediated remodeling of resistance arteries. It should be noted that an association between desmin and caveolin has been described in vascular cells, 41 and that we have previously shown that HF remodeling is also exaggerated in desmin knockout mice. 16 However, although the present study reveals for the first time A and B) and protein (C) expression levels of caveolin-1 (CAV-1) determined in mesenteric arteries submitted chronically to high flow (HF) or normal flow (NF) and isolated for analysis after 2 or 4 days (day 2 or day 4). Arteries were isolated from ovariectomized (OVX) rats treated with 17-β-estradiol (E2) or left untreated. Mean±SEM is represented (n=12 rats per group). In estrogen receptor (ER)α knockout mice, eNOS and CAV-1 mRNA (D) levels were determined in NF and HF arteries (n=6 measurements obtained from 12 mice per group). *P<0.05, HF vs NF arteries. the inhibitory role of caveolin-1 in flow-mediated remodeling of resistance arteries, caveolin-1 did not appear to have an impact on the effect of E2 in this process. This differs from several short-term effects of E2 in large arteries, where the role of caveolin-1 in regulating eNOS activity has been thoroughly described. For instance, caveolin-1 has been shown to be required in activating eNOS and NO production by E2 in the rat aorta, 42 and the ERα-mediated nongenomic activation of eNOS requires functional caveolae. 43 Indeed, caveolin-1 plays a major role in the activation of eNOS by estrogen through a rapid nongenomic estrogen action within the plasma membrane. 44 We also found that both VEGF A and HIF1α expression were increased in HF arteries from E2-treated mice at day 4, and could thereby be in the remodeling process. These factors are known to be involved in collateral growth during postischemic revascularization, 45 as well as involved in the effect E2 has on reendothelialization and intimal hyperplasia. 46 VEGF also mediates the estrogen-induced increase in microvascular permeability and endothelial cell proliferation in the primate endometrium. 47
Conclusion
These findings show for the first time that chronic increases in blood flow in resistance arteries in vivo induce a structural remodeling, which is totally dependent on either endogenous or exogenous estradiol. This action relies on ERα activation, and more specifically on endothelial ERα. Thus, modulation of ERα by E2 or by selective ER modulators could now be considered to improve blood perfusion in ischemic conditions, along with the major antiischemic and angiogenic properties of estrogens.
